Table 1.
Clinicopathological characteristics of patients correlated with the pathway mutational status.
| None | PI3K | Chi-squared p value | WNT | Chi-squared p value | Both (PI3K and WNT) | Chi-squared p value | ||
|---|---|---|---|---|---|---|---|---|
| Number of patients | 236 (33,5%) | 56 (7,9%) | 346 (49,1%) | 67 (9,5%) | ||||
| Sex | 0.939 | 0.614 | 0.838 | |||||
| Female | 113 (49,1%) | 21 (51,2%) | 147 (51,8%) | 31 (51,7%) | ||||
| Male | 117 (50,9%) | 20 (48,8%) | 137 (48,2%) | 29 (48,3%) | ||||
| Tumor Location | 0.128 | 0.00022 * | 0.765 | |||||
| Right | 103 (50%) | 27 (67,5%) | 102 (34,8%) | 30 (46,9%) | ||||
| Left | 64 (31,1%) | 8 (20%) | 91 (31,1%) | 23 (35,9%) | ||||
| Rectum | 39 (18,9%) | 5 (12,5%) | 100 (34,1%) | 11 (17,2%) | ||||
| Stage | 0.00619 * | 0.015 * | 0.196 | |||||
| I & II | 72 (32,1%) | 22 (56,4%) | 111 (43,4%) | 23 (42,6%) | ||||
| III & IV | 152 (67,9%) | 17 (43,6%) | 145 (56,6%) | 31 (57,4%) | ||||
| Age of Onset | 0.42 | 0.045 * | 0.062 | |||||
| Early Onset (<50) | 24 (10,6%) | 2 (5%) | 14 (5,3%) | 1 (1,7%) | ||||
| Late Onset (>50) | 203 (89,4%) | 38 (95%) | 250 (94,7%) | 57 (98,3%) | ||||
| MSI | 0.094 | 0.00507 * | 0.606 | |||||
| MSI | 17 (16,3%) | 14 (29,8%) | 11 (5,7%) | 11 (21,2%) | ||||
| MSS | 87 (83,7%) | 33 (70,2%) | 183 (94,3%) | 41 (78,8%) | ||||
Note: Significance was considered when * p < 0.05